Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (An American Ophthalmological Society Thesis)

Transactions of the American Ophthalmological Society

Volumn 104, Issue , 2006, Pages 264-302

  Azar, Dimitri T ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; COLLAGENASE 3; ENDOSTATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 18; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 23; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; PIGMENT EPITHELIUM DERIVED FACTOR; RESTIN; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; AQUEOUS HUMOR; ARTICLE; BODY TEMPERATURE; CORNEA; CORNEA EPITHELIUM; CORNEA INJURY; CORNEA LIMBUS; CORNEA NEOVASCULARIZATION; CORNEA VASCULARIZATION; EPITHELIZATION; FIBROBLAST; HUMAN; HYDRATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; INNERVATION; IRRADIATION; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANGIOSTATINS; ANIMALS; BLOTTING, WESTERN; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOSTATINS; EYE PROTEINS; FIBROBLAST GROWTH FACTOR 2; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 33947651126     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (252)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-249.
2. Arnold J. Experimentelle Untersuchungen uber die Entwicklung. Virchows Archiv für pathologische Anatomie 1872;54:1-30.
3. Cogan DG. Corneal vascularization. Invest Ophthalmol Vis Sci 1962;1:253-261.
4. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998;17:611-613.
5. Timar J, Dome B, Fazekas K, et al. Angiogenesis-dependent diseases and angiogenesis therapy. Pathol Oncol Res 2001;7:85-94.
6. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931- 10934.
7. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea 1995;14:604-609.
8. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004;45:1117-1124.
9. Gabison E, Chang JH, Hernandez-Quintela E, et al. Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res 2004;78:579-589.
10. Kato T, Chang JH, Azar DT. Expression of type XVIII collagen during healing of corneal incisions and keratectomy wounds. Invest Ophthalmol Vis Sci 2003;44:78-85.
11. Kato T, Kure T, Chang JH, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2001;508:187-190.
12. Kure T, Chang JH, Kato T, et al. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest Ophthalmol Vis Sci 2003;44:137-144.
13. Lin HC, Chang JH, Jain S, et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001;42:2517-2524.
14. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-228.
15. Beck L Jr, D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J 1997;11:365-373.
16. Asahara T, Isner JM. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 2002;11:171-178.
17. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999;18:3964-3972.
18. Cohen MM Jr. Vasculogenesis, angiogenesis, hemangiomas, and vascular malformations. Am J Med Genet 2002;108:265-274.
19. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
20. Chan CK, Pham LN, Zhou J, et al. Differential expression of pro- and anti- angiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization. Lab Invest 2005;85:721-733.
21. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-269.
22. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004;45:2666-2673.
23. Bazan HE. Cellular and molecular events in corneal wound healing: significance of lipid signalling. Exp Eye Res 2005;80:453-463.
24. Volker-Dieben HJ, D'Amaro J, Kok-van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol 1987;15:11-18.
25. Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of corneal graft rejection in the United Kingdom. Cornea 2005;24:292-296.
26. Kremer I, Cohen EJ, Eagle RC, et al. Histopathologic evaluation of stromal inflammation in Acanthamoeba keratitis. CLAO J 1994;20:45-48.
27. Netto MV, Mohan RR, Ambrosio R Jr, et al. Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea 2005;24:509-522.
28. Wilson SE. Role of apoptosis in wound healing in the cornea. Cornea 2000;19:S7-12.
29. Fini ME. Keratocyte and fibroblast phenotypes in the repairing cornea. Prog Retin Eye Res 1999;18:529-551.
30. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 2002;21:1-14.
31. Jester JV, Petroll WM, Barry PA, et al. Expression of alpha-smooth muscle (alpha-SM) actin during corneal stromal wound healing. Invest Ophthalmol Vis Sci 1995;36:809-819.
32. You L, Kruse FE. Differential effect of activin A and BMP-7 on myofibroblast differentiation and the role of the Smad signaling pathway. Invest Ophthalmol Vis Sci 2002;43:72-81.
33. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
34. Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-111.
35. Ronnov-Jessen L, Petersen OW. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1993;68:696-707.
36. Jester JV, Barry-Lane PA, Cavanagh HD, et al. Induction of alpha-smooth muscle actin expression and myofibroblast transformation in cultured corneal keratocytes. Cornea 1996;15:505-516.
37. Maltseva O, Folger P, Zekaria D, et al. Fibroblast growth factor reversal of the corneal myofibroblast phenotype. Invest Ophthalmol Vis Sci 2001;42:2490-2495.
38. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997;389:618-622.
39. Lawler S, Feng XH, Chen RH, et al. The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 1997;272:14850-14859.
40. Masur SK, Dewal HS, Dinh TT, et al. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc Natl Acad Sci U S A 1996;93:4219-4223.
41. Zimmerman CM, Padgett RW. Transforming growth factor beta signaling mediators and modulators. Gene 2000;249:17-30.
42. Rodrigues MM, Waring III G, Hackett J. Cornea. In Jakobiec FA, ed. Ocular Anatomy, Embryology, and Teratology. Philadelphia: Harper & Row; 1982.
43. Hogan MJ, Alvarado JA, Wedell JE. Histology of the Human Eye. Philadelphia: WB Saunders; 1971.
44. Gipson IK, Joyce NC, Zieske JD. The anatomy and cell biology of the human cornea, limbus, conjunctiva, and adnexa. In: Foster CS, Azar DT, Dohlman CH, eds. The Cornea Scientific Foundations & Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:1-35.
45. Martola EL, Dohlman CH. Silicone oil in the anterior chamber of the eye. Effect on corneal hydration. Acta Ophthalmol (Copenh) 1963;41:75-79.
46. Anseth A, Dohlman CH. Influence of the intraocular pressure on hydration of the corneal stroma. Acta Ophthalmol (Copenh) 1957;35:85-90.
47. Klyce SD. Stromal lactate accumulation can account for corneal oedema osmotically following epithelial hypoxia in the rabbit. J Physiol 1981;321:49-64.
48. Kwok LS, Klyce SD. Theoretical basis for an anomalous temperature coefficient in swelling pressure of rabbit corneal stroma. Biophys J 1990;57:657-662.
49. Cogan DG. Vascularization of the cornea. Its experimental induction by small lesions and a new theory of its pathogenesis. Arch Ophthalmol 1949;41:406-416.
50. Cursiefen C, Hofmann-Rummelt C, Kuchle M, et al. Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol 2003;87:101-106.
51. Clark ER, Clark EL. Observations on living performed blood vessels as seen in a transparent chamber inserted into the rabbit's ear. Am J Anat 1932;49:441.
52. Ashton N. Cornea vascularization. In: Duke-Elder S, Perkins ES, eds. The transparency of the cornea. A symposium. Oxford, England: Blackwell Scientific Publications; 1960:131-147.
53. Langham ME. Observations on the growth of blood vessels into the cornea. Application of a new experimental technique. Br J Ophthalmol 1953;37:210-222.
54. Swindle PF. Events of vascularization and devascularization seen in corneas. Arch Ophthalmol 1938;20:974-995.
55. Ashton N, Cook C. Mechanism of corneal vascularization. Br J Ophthalmol 1953;37:193-209.
56. Heydenreich A. [Corneal vascularization in animal experiment.] Klin Monatsbl Augenheilkd 1955;127:465-471.
57. Bessiere E, Teulieres J. [Experimental vascularization of the cornea.] Arch Ophtalmol Rev Gen Ophtalmol 1951;11:268-271.
58. Levene R, Shapiro A, Baum J. Experimental corneal vascularization. Arch Ophthalmol 1963;70:242-249.
59. Maurice DM, Zauberman H, Michaelson IC. The stimulus to neovascularization in the cornea. Exp Eye Res 1966;5:168-184.
60. Rowson NJ, Dart JK, Buckley RJ. Corneal neovascularisation in acute hydrops. Eye 1992;6:404-406.
61. Baum JL, Martola EL. Corneal edema and corneal vascularization. Am J Ophthalmol 1968;65:881-884.
62. Brown SI, McLean JM. Peripheral corneal edema after cataract extraction. A new clinical entity. Trans Am Acad Ophthalmol Otolaryngol 1969;73:465-470.
63. Charlin R. Peripheral corneal edema after cataract extraction. Am J Ophthalmol 1985;99:298-303.
64. Reed JW, Cain LR, Weaver RG, Oberfeld SM. Clinical and pathologic findings of aphakic peripheral corneal edema: Brown-McLean syndrome. Cornea 1992;11:577-583.
65. Gothard TW, Hardten DR, Lane SS, et al. Clinical findings in Brown-McLean syndrome. Am J Ophthalmol 1993;115:729-737.
66. Klintworth GK, Burger PC. Neovascularization of the cornea: current concepts of its pathogenesis. Int Ophthalmol Clin 1983;23:27-39.
67. Eliason JA. Leukocytes and experimental corneal vascularization. Invest Ophthalmol Vis Sci 1978;17:1087-1095.
68. Eliason JA, Elliott JP. Proliferation of vascular endothelial cells stimulated in vitro by corneal epithelium. Invest Ophthalmol Vis Sci 1987;28:1963-1969.
69. van Setten G. Vascular endothelial growth factor (VEGF) in normal human corneal epithelium: detection and physiological importance. Acta Ophthalmol Scand 1995;27:317-321.
70. Sunderkotter C, Roth J, Sorg C. Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea. Am J Pathol 1990;3:511-515.
71. Sholley MM, Cavallo T, Cotran RS. Endothelial proliferation in inflammation. I. Autoradiographic studies following thermal injury to the skin of normal rats. Am J Pathol 1977;89:277-296.
72. Sholley MM, Cotran RS. Endothelial proliferation in inflammation. II. Autoradiographic studies in x-irradiated leukopenic rats after thermal injury to the skin. Am J Pathol 1978;91:229-242.
73. Kaminski M, Kaminska G. Inhibition of lymphocyte-induced angiogenesis by enzymatically isolated rabbit cornea cells. Arch Immunol Ther Exp (Warsz) 1978;26:1079-1082.
74. Ma DH, Tsai RJ, Chu WK, et al. Inhibition of vascular endothelial cell morphogenesis in cultures by limbal epithelial cells. Invest Ophthalmol Vis Sci 1999;40:1822-1828.
75. Sholley MM, Gimbrone MA Jr, Cotran RS. The effects of leukocyte depletion on corneal neovascularization. Lab Invest 1978;38:32-40.
76. Nakayasu K, Hayashi N, Okisaka S, et al. Formation of capillary-like tubes by vascular endothelial cells cocultivated with keratocytes. Invest Ophthalmol Vis Sci 1992;33:3050-3057.
77. Klintworth GK. The hamster cheek pouch: an experimental model of corneal vascularization. Am J Pathol 1973;73:691-710.
78. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. Am J Pathol 1975;79:537-554.
79. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. II. Studies on the effect of leukocytic elimination on corneal vascularization. Am J Pathol 1975;81:531-544.
80. Fromer CH, Klintworth GK. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal vascularization. III. Studies related to the vasoproliferative capability of polymorphonuclear leukocytes and lymphocytes. Am J Pathol 1976;82:157-170.
81. Eliason JA. Angiogenic activity of the corneal epithelium. Exp Eye Res 1985;41:721-732.
82. Schanzlin DJ, Cyr RJ, Friedlaender MH. Histopathology of corneal neovascularization. Arch Ophthalmol 1983;101:472-474.
83. Ryu S, Albert DM. Evaluation of tumor angiogenesis factor with the rabbit cornea model. Invest Ophthalmol Vis Sci 1979;18:831-841.
84. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-1378.
85. Folkman J, Langer R, Linhardt RJ, et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-725.
86. Frank SG, Kavaliunas DR. Investigation of the beta-cyclodextrin- hydrocortisone inclusion compound. J Pharm Sci 1983;72:1215-1217.
87. Proia AD, Hirakata A, McInnes JS, et al. The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res 1993;57:693-698.
88. Li WW, Casey R, Gonzalez EM, et al. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci 1991;32:2898-2905.
89. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
90. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000;70:419-428.
91. Mastyugin V, Mosaed S, Bonazzi A, et al. Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 2001;23:1-10.
92. Breier G. Angiogenesis in embryonic development - a review. Placenta 2000;21 Suppl A:S11-15.
93. Darland DC, D'Amore PA. Cell-cell interactions in vascular development. Curr Top Dev Biol 2001;52:107-149.
94. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001;106:148-156.
95. Ng IO, Poon RT, Lee JM, et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001;116:838-845.
96. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001;220:112-121.
97. Masuda Y, Shimizu A, Mori T, et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001;159:599-608.
98. Shima DT, Kuroki M, Deutsch U, et al. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 1996;271:3877-3883.
99. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001;61:6952-6957.
100. Bjorndahl MA, Cao R, Burton JB, et al. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res 2005;65:9261-9268.
101. Sugihara T, Wadhwa R, Kaul SC, et al. A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115. J Biol Chem 1998;273:3033-3038.
102. Olofsson B, Jeltsch M, Eriksson U, et al. Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol 1999;10:528-535.
103. Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001;33:421-426.
104. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005;5:735-743.
105. Tammela T, Petrova TV, Alitalo K. Molecular lymphangiogenesis: new players. Trends Cell Biol 2005;15:434-441.
106. Zawieja D. Lymphatic biology and the microcirculation: past, present and future. Microcirculation 2005;12:141-150.
107. Zhang HT, Scott PA, Morbidelli L, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000;83:63-68.
108. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001;75:9828-9835.
109. Schlaeppi JM, Siemeister G, Weindel K, et al. Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor. J Cancer Res Clin Oncol 1999;125:336-342.
110. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J 2000;19:1525-1533.
111. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A. 2000;97:4052-4057.
112. Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. Embo J 1998;17:5896-5904.
113. Jeffers M, Shimkets R, Prayaga S, et al. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res 2001;61:3131-3138.
114. Adamis AP, Meklir B, Joyce NC. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol 1991;139:961-967.
115. Soubrane G, Jerdan J, Karpouzas I, et al. Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 1990;31:323-333.
116. Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct antitumor properties. J Biol Chem 2000;275:23745-23750.
117. Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001;276:15240-15248.
118. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-143.
119. Maeshima Y, Yerramalla UL, Dhanabal M, et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem 2001;276:31959-31968.
120. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86:346-355.
121. Engsig MT, Chen QJ, Vu TH, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000;151:879-889.
122. Zhang H, Li C, Baciu PC. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2002;43:955-962.
123. Toschi E, Barillari G, Sgadari C, et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001;12:2934-2946.
124. Seiki M. Membrane-type matrix metalloproteinases. APMIS 1999;107:137-143.
125. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-65.
126. Takino T, Sato H, Shinagawa A,et al. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 1995;270:23013-23020.
127. Puente XS, Pendas AM, Llano E, et al. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996;56:944-949.
128. Shofuda K, Yasumitsu H, Nishihashi A, et al. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. J Biol Chem 1997;272:9749-9754.
129. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem 1999;274:8925-8932.
130. Tomasek JJ, Halliday NL, Updike DL, et al. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. J Biol Chem 1997;272:7482-7487.
131. Ye HQ, Azar DT. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. Invest Ophthalmol Vis Sci 1998;39:913-921.
132. Williamson RA, Hutton M, Vogt G, et al. Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14. J Biol Chem 2001;276:32966-32970.
133. Williamson RA, Muskett FW, Howard MJ, et al. The effect of matrix metalloproteinase complex formation on the conformational mobility of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Biol Chem 1999;274:37226-37232.
134. Bernardo MM, Brown S, Li ZH, et al. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem 2002;277:11201-11207.
135. Jakobiec FA, Ozanics V. General topographic anatomy of the eye. In: Jakobiec FA, ed. Ocular Anatomy, Embryology, Teratology. Philadelphia: Harper & Row; 1982.
136. Van Buskirk EM. The anatomy of the limbus. Eye 1989;3:101-108.
137. Gipson IK, Joyce NC. Anatomy and cell biology of the cornea, superficial limbus and conjunctiva. Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd ed. Philadelphia: WB Saunders; 1999:612-629.
138. Duke-Elder S. Corneal Wound Healing. Duke-Elder S, ed. London: Henry Klimpton; 1958:491.
139. Davanger M, Evensen A. Role of the pericorneal papillary structure in renewal of corneal epithelium. Nature 1971;229:560-561.
140. Thoft RA, Friend J. Biochemical transformation of regenerating ocular surface epithelium. Invest Ophthalmol Vis Sci 1977;16:14-20.
141. Thoft RA. The role of the limbus in ocular surface maintenance and repair. Acta Ophthalmol Suppl 1989;192:91-94.
142. Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Limbal epithelium in ocular surface wound healing. Invest Ophthalmol Vis Sci 1982;23:73-80.
143. Wei ZG, Sun TT, Lavker RM. Rabbit conjunctival and corneal epithelial cells belong to two separate lineages. Invest Ophthalmol Vis Sci 1996;37:523-533.
144. Gipson IK. The epithelial basement membrane zone of the limbus. Eye 1989;3:132-140.
145. Schermer A, Galvin S, Sun TT. Differentiation-related expression of a major 64K corneal keratin in vivo and in culture suggests limbal location of corneal epithelial stem cells. J Cell Biol 1986;103:49-62.
146. Zieske JD. Perpetuation of stem cells in the eye. Eye 1994;8:163-169.
147. Kruse FE. Stem cells and corneal epithelial regeneration. Eye 1994;8:170-183.
148. Schlotzer-Schrehardt U, Kruse FE. Identification and characterization of limbal stem cells. Exp Eye Res 2005;81:247-264.
149. Friedenwald JS. Growth pressure and metaplasia of conjunctival and corneal epithelium. Doc Ophthalmol 1951;5:184-192.
150. Huang AJ, Tseng SC. Corneal epithelial wound healing in the absence of limbal epithelium. Invest Ophthalmol Vis Sci 1991;32:96-105.
151. Tseng SC. Concept and application of limbal stem cells. Eye 1989;3:141-157.
152. Dua HS, Forrester JV. The corneoscleral limbus in human corneal epithelial wound healing. Am J Ophthalmol 1990;110:646-656.
153. Espana EM, Grueterich M, Romano AC, et al. Idiopathic limbal stem cell deficiency. Ophthalmology 2002;109:2004-2010.
154. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. Ophthalmology 1989;96:709-722.
155. Javier JA, Khondkaryan A, Lee JB. Hemilimbal deficiency model of corneal neovascularization: possible invalidity of the limbal barrier concept. Klin Monatsbl Augenheilkd 2006. In press.
156. Narasaki R, Kuribayashi H, Shimizu K, et al. Bacillolysin MA, a novel bacterial metalloproteinase that produces angiostatin-like fragments from plasminogen and activates protease zymogens in the coagulation and fibrinolysis systems. J Biol Chem 2005;280:14278-14287.
157. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
158. Cao W, Tombran-Tink J, Chen W, et al. Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. J Neurosci Res 1999;57:789-800.
159. Shin SH, Kim JC, Chang SI, et al. Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea 2000;19:212-217.
160. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
161. Vazquez F, Hastings G, Ortega MA, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999;274:23349-23357.
162. Chang JH, Javier JA, Chang GY, et al. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett 2005;579:3601-3606.
163. Ambati BK, Joussen AM, Ambati J, et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002;120:1063-1068.
164. Kisker O, Onizuka S, Banyard J, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001;61:7298-7304.
165. Perri SR, Nalbantoglu J, Annabi B, et al. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res 2005;65:8359-65.
166. Dell'Eva R, Pfeffer U, Indraccolo S, et al. Inhibition of tumor angiogensis by angiostatin: from recombinant protein to gene therapy. Endothelium 2002;9:3-10
167. Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-1804.
168. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-28825.
169. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-6852.
170. Lijnen HR, Ugwu F, Bini A, et al. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998;37:4699-4702.
171. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A. 1999;96:2811-2816.
172. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 2001;276:39562-39568.
173. Griscelli F, Li H, Bennaceur-Griscelli A, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A 1998;95:6367-6372.
174. Shepard SR, Boucher R, Johnston J, et al. Large-scale purification of recombinant human angiostatin. Protein Expr Purif 2000;20:216-227.
175. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. Embo J 2002;21:1535-1544.
176. Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999;255:735-739.
177. John H, Schulz S, Forssmann WG, et al. Time-resolved fluorometric assay for the detection of endostatin in chromatographically separated extracts of natural peptides. J Immunol Methods 2002;268:233-237.
178. Morimoto T, Aoyagi M, Tamaki M, et al. Increased levels of tissue endostatin in human malignant gliomas. Clin Cancer Res 2002;8:2933-2938.
179. Tomono Y, Naito I, Ando K, et al. Epitope-defined monoclonal antibodies against multiplexin collagens demonstrate that type XV and XVIII collagens are expressed in specialized basement membranes. Cell Struct Funct 2002;27:9-20.
180. Wen W, Moses MA, Wiederschain D, et al. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6056.
181. Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. Embo J 2000;19:1187-1194.
182. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-251.
183. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-27879.
184. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-11726.
185. Pasco S, Brassart B, Ramont L, et al. Control of melanoma cell invasion by type IV collagen. Cancer Detect Prev 2005;29:260-266.
186. Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A 2005;102:2934-2939.
187. Magnon C, Galaup A, Mullan B, et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res 2005;65:4353-4361.
188. Sudhakar A, Nyberg P, Keshamouni VG, et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 2005;115:2801-2810.
189. Turner AN, Rees AJ. Goodpasture's disease and Alport's syndromes. Annu Rev Med 1996;47:377-386.
190. Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60:2520-2526.
191. Kamphaus GD, Colorado PC, Panka DJ, et al. A novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-1215.
192. Meyer C, Notari L, Becerra SP. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 2002;277:45400-45407.
193. Kenyon BM, Voest EE, Chen CC, et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37:1625-1632.
194. Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
195. Wilson CL, Heppner KJ, Labosky PA, et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997;94:1402-1407.
196. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-248.
197. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-285.
198. Lu PC, Ye H, Maeda M, Azar DT. Immunolocalization and gene expression of matrilysin during corneal wound healing. Invest Ophthalmol Vis Sci 1999;40:20-27.
199. Ozerdam UA, Alitalo KS, Li PA. Contribution of bone-marrow derived perciyte precursor cells to corneal vasculogenesis. Invest Ophthalmol Vis Sci 2005;46:3502-3506.
200. Bix G, Iozzo RV. Matrix revolutions: "tails" of basement-membrane components with angiostatic functions. Trends Cell Biol 2005;15:52-60.
201. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A. 2001;98:1024-1029.
202. Javaherian K, Park SY, Pickl WF, et al. Laminin modulates morphogenic properties of the collagen XVIII endostatin domain. J Biol Chem 2002;277:45211-45218.
203. MacDonald NJ, Shivers WY, Narum DL,. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-25196.
204. Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002;519:147-152.
205. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-822.
206. Urbich C, Reissner A, Chavakis E, et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the antiangiogenic effects of endostatin. FASEB J 2002;16:706-708.
207. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J 2001;15:1044-1053.
208. Hanai J, Gloy J, Karumanchi SA, et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 2002;158:529-539.
209. Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002;277:16464-16469.
210. Oh SP, Kamagata Y, Muragaki Y, et al. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci U S A 1994;91:4229-4233.
211. Oh SP, Warman ML, Seldin MF, et al. Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the alpha 1(XVIII) collagen gene to mouse chromosome 10 and human chromosome 21. Genomics 1994;19:494-499.
212. Rehn M, Hintikka E, Pihlajaniemi T. Primary structure of the alpha 1 chain of mouse type XVIII collagen, partial structure of the corresponding gene, and comparison of the alpha 1(XVIII) chain with its homologue, the alpha 1(XV) collagen chain. J Biol Chem 1994;269:13929-13935.
213. Sasaki T, Fukai N, Mann K, et al. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. Embo J 1998;17:4249-4256.
214. Saarela J, Rehn M, Oikarinen A, et al. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 1998;153:611-626.
215. Chang, JH, Javier JA, Chang GY, et al. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type VIII collagen. FEBS Lett 2005;579:3601-3606.
216. Muragaki Y, Timmons S, Griffith CM, et al. Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci U S A 1995;92:8763-8767.
217. Halfter W, Dong S, Schurer B, et al. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 1998;273:25404-25412.
218. Liesegang TJ. Physiologic changes of the cornea with contact lens wear. CLAO J 2002;28:12-27.
219. Hamill MB. Corneal and scleral trauma. Ophthalmol Clin North Am 2002;15:185-194.
220. Power WJ, Tugal-Tutkun I, Foster CS. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology 1998;105:637-642.
221. Koch AE, Volin MV, Woods JM, et al. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 2001;44:31-40.
222. Austin P, Brown SI. Inflammatory Terrien's marginal corneal disease. Am J Ophthalmol 1981;92:189-192.
223. Centifanto-Fitzgerald YM, Yamaguchi T, et al. Ocular disease pattern induced by herpes simplex virus is genetically determined by a specific region of viral DNA. J Exp Med 1982;155:475-489.
224. Feder RS, Krachmer JH. Conjunctival resection for the treatment of the rheumatoid corneal ulceration. Ophthalmology 1984;91:111-115.
225. Nishiwaki-Dantas MC, Dantas PE, Reggi JR. Ipsilateral limbal translocation for treatment of partial limbal deficiency secondary to ocular alkali burn. Br J Ophthalmol 2001;85:1031-1033.
226. Chen J, Xu J. [Early corneal limbal autograft transplantation after alkali burns]. Chung Hua Yen Ko Tsa Chih 1997;33:233-235.
227. Nishida K, Kinoshita S, Ohashi Y, et al. Ocular surface abnormalities in aniridia. Am J Ophthalmol 1995;120:368-375.
228. Tijmes NT, Zaal MJ, De Jong PT, et al. Two families with dyshidrotic ectodermal dysplasia associated with ingrowth of corneal vessels, limbal hair growth, and Bitot-like conjunctival anomalies. Ophthalmic Genet 1997;18:185-192.
229. Berman MB. Regulation of corneal fibroblast MMP-1 secretion by cytochalasins. Cornea 1994;13:51-57.
230. Tao Y, Bazan HE, Bazan NG. Platelet-activating factor induces the expression of metalloproteinases-1 and -9, but not -2 or -3, in the corneal epithelium. Invest Ophthalmol Vis Sci 1995;36:345-354.
231. Maguen E, Zorapapel NC, Zieske JD, et al. Extracellular matrix and matrix metalloproteinase changes in human corneas after complicated laser-assisted in situ keratomileusis (LASIK). Cornea 2002;21:95-100.
232. Reed MJ, Corsa AC, Kudravi SA, et al. A deficit in collagenase activity contributes to impaired migration of aged microvascular endothelial cells. J Cell Biochem 2000;77:116-126.
233. Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000;19:1102-1113.
234. Saghizadeh M, Brown DJ, Castellon R, et al. Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. Am J Pathol 2001;158:723-734.
235. O'Brien TP, Li QJ, Sauerburger F, et al. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001;108:656-659.
236. Mahajan VB, Wei C, McDonnell PJ 3rd. Microarray analysis of corneal fibroblast gene expression after interleukin-1 treatment. Invest Ophthalmol Vis Sci 2002;43:2143-2151.
237. Dong Z, Ghabrial M, Katar M, et al. Membrane-type matrix metalloproteinases in mice intracorneally infected with Pseudomonas aeruginosa. Invest Ophthalmol Vis Sci 2000;41:4189-4194.
238. Dushku N, John MK, Schultz GS, et al. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol 2001;119:695-706.
239. Dong Z, Katar M, Alousi S, et al. Expression of membrane-type matrix metalloproteinases 4, 5, and 6 in mouse corneas infected with P aeruginosa. Invest Ophthalmol Vis Sci 2001;42:3223-3227.
240. Ballaun C, Weninger W, Uthman A, et al. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol 1995;104:7-10.
241. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995;270:12607-12613.
242. Detmar M, Yeo KT, Nagy JA, et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995;105:44-50.
243. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
244. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
245. Kleespies A, Guba M, Jauch KW, et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95-104.
246. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 2004;4:125-146.
247. Kim B, Tang Q, Biswas PS, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004;165:2177-2185.
248. Rota R, Riccioni T, Zaccarini M, et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 2004;6:992-1002.
249. Bainbridge JW, Jia H, Bagherzadeh A, et al. A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. Biochem Biophys Res Commun 2003;302:793-799.
250. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-1196.
251. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522.e1-1522.e14.
252. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.